Therapeutic Response

v::RET status confers therapeutic sensitivity to Pralsetinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Gavreto (pralsetinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to pralsetinib for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as detected by an FDA approved test (NSCLC).
Gavreto (pralsetinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized pralsetinib as a monotherapy treatment for adult patients with RET fusion-positive advanced non-small cell lung cancer (NSCLC) who have not previously been treated with a RET inhibitor.